JP2002540217A - イヌアレルギー用ペプチドワクチン - Google Patents
イヌアレルギー用ペプチドワクチンInfo
- Publication number
- JP2002540217A JP2002540217A JP2000608048A JP2000608048A JP2002540217A JP 2002540217 A JP2002540217 A JP 2002540217A JP 2000608048 A JP2000608048 A JP 2000608048A JP 2000608048 A JP2000608048 A JP 2000608048A JP 2002540217 A JP2002540217 A JP 2002540217A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- ige
- blank
- proline
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020751 Hypersensitivity Diseases 0.000 title description 25
- 230000007815 allergy Effects 0.000 title description 24
- 208000026935 allergic disease Diseases 0.000 title description 23
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 297
- 150000001413 amino acids Chemical class 0.000 claims abstract description 70
- 241000282465 Canis Species 0.000 claims abstract description 50
- 241000700605 Viruses Species 0.000 claims abstract description 43
- 239000002245 particle Substances 0.000 claims abstract description 28
- 239000004475 Arginine Substances 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 claims description 113
- 229940024606 amino acid Drugs 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 41
- 230000028993 immune response Effects 0.000 claims description 29
- 239000002671 adjuvant Substances 0.000 claims description 26
- 208000010668 atopic eczema Diseases 0.000 claims description 19
- 230000002163 immunogen Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 230000000172 allergic effect Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 208000011580 syndromic disease Diseases 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- ZPSABJGMGWSPSD-QFMMGIBTSA-N 2-aminoacetic acid (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid (2S,3R)-2-amino-3-hydroxybutanoic acid (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid (2S)-2-amino-3-hydroxypropanoic acid (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid (2S)-2-amino-4-methylpentanoic acid (2S)-2-amino-4-methylsulfanylbutanoic acid (2S)-2-aminopentanedioic acid (2S)-2,6-diaminohexanoic acid (2S)-2,4-diamino-4-oxobutanoic acid Chemical compound N[C@@H](CCCCN)C(=O)O.N[C@@H](CO)C(=O)O.N[C@@H](CCC(=O)O)C(=O)O.N[C@@H](CCCNC(N)=N)C(=O)O.N[C@@H](CC1=CC=C(C=C1)O)C(=O)O.N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O.N[C@@H]([C@H](O)C)C(=O)O.N[C@@H](CC(C)C)C(=O)O.N[C@@H](CC(N)=O)C(=O)O.N[C@@H](CCSC)C(=O)O.NCC(=O)O ZPSABJGMGWSPSD-QFMMGIBTSA-N 0.000 claims description 2
- BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 85
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 102000004169 proteins and genes Human genes 0.000 abstract description 27
- 239000000969 carrier Substances 0.000 abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 79
- 239000007790 solid phase Substances 0.000 description 63
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 40
- 210000003719 b-lymphocyte Anatomy 0.000 description 32
- 230000004044 response Effects 0.000 description 30
- 210000003630 histaminocyte Anatomy 0.000 description 29
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 241000196324 Embryophyta Species 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 230000003053 immunization Effects 0.000 description 15
- 238000002649 immunization Methods 0.000 description 15
- 230000009870 specific binding Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 235000018417 cysteine Nutrition 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 108010073816 IgE Receptors Proteins 0.000 description 12
- 102000009438 IgE Receptors Human genes 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000016784 immunoglobulin production Effects 0.000 description 11
- 238000002823 phage display Methods 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 238000013459 approach Methods 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 239000013566 allergen Substances 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000001806 memory b lymphocyte Anatomy 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 101710132601 Capsid protein Proteins 0.000 description 5
- 101710094648 Coat protein Proteins 0.000 description 5
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 5
- 108700024394 Exon Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 5
- 101710125418 Major capsid protein Proteins 0.000 description 5
- 101710141454 Nucleoprotein Proteins 0.000 description 5
- 101710083689 Probable capsid protein Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 150000001945 cysteines Chemical class 0.000 description 5
- 229960003067 cystine Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108010073443 Ribi adjuvant Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 241000219977 Vigna Species 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002516 postimmunization Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 241000867607 Chlorocebus sabaeus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 230000010807 negative regulation of binding Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000347972 Caucasus prunus virus Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 101150013191 E gene Proteins 0.000 description 1
- 101150067056 Epsilon gene Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 101100219325 Phaseolus vulgaris BA13 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000010722 Vigna unguiculata Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 108010008429 immunoglobulin-binding factors Proteins 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 phosphate ester Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28176199A | 1999-03-30 | 1999-03-30 | |
| US09/281,761 | 1999-03-30 | ||
| PCT/US2000/008523 WO2000058349A1 (fr) | 1999-03-30 | 2000-03-30 | Vaccin peptidique pour allergie canine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002540217A true JP2002540217A (ja) | 2002-11-26 |
Family
ID=23078685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000608048A Pending JP2002540217A (ja) | 1999-03-30 | 2000-03-30 | イヌアレルギー用ペプチドワクチン |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1082340A1 (fr) |
| JP (1) | JP2002540217A (fr) |
| AU (1) | AU4053600A (fr) |
| CA (1) | CA2329152A1 (fr) |
| WO (1) | WO2000058349A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007520545A (ja) * | 2004-02-05 | 2007-07-26 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | 抗アレルギー組成物及び関連方法 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393529B2 (en) | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| JP2007526919A (ja) * | 2004-03-05 | 2007-09-20 | バイオ−ラッド ラボラトリーズ，インコーポレイティド | 糖タンパク質ｇ２ペプチドを用いたｈｓｖ−２型特異的免疫検定 |
| EP1872792A1 (fr) | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | Méthode pour la production d'un allergène hydrolysé |
| WO2010128372A1 (fr) | 2009-05-08 | 2010-11-11 | Allergosystem S.R.L. | Dispositif de protection d'animaux de compagnie d'une allergie |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009628A1 (fr) * | 1990-11-23 | 1992-06-11 | Immunodynamics, Inc. | Peptides immunoactifs synthetiques presentant une activite immunomodulante et therapeutique |
| DE4134814A1 (de) * | 1991-10-22 | 1993-04-29 | Basf Ag | Neues thrombininhibitorisches protein aus zecken |
| CA2157510A1 (fr) * | 1993-03-05 | 1994-09-15 | Howard M. Grey | Peptides liants hla-a2.1 et leurs utilisations |
| CA2173138A1 (fr) * | 1993-10-19 | 1995-04-27 | Masafumi Takiguchi | Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida |
| JPH08151396A (ja) * | 1994-11-28 | 1996-06-11 | Teijin Ltd | Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤 |
| US5700675A (en) * | 1995-12-13 | 1997-12-23 | Regents Of The University Of California | Protein kinase required for Ras signal transduction |
-
2000
- 2000-03-30 EP EP00919927A patent/EP1082340A1/fr not_active Withdrawn
- 2000-03-30 JP JP2000608048A patent/JP2002540217A/ja active Pending
- 2000-03-30 AU AU40536/00A patent/AU4053600A/en not_active Abandoned
- 2000-03-30 WO PCT/US2000/008523 patent/WO2000058349A1/fr not_active Application Discontinuation
- 2000-03-30 CA CA002329152A patent/CA2329152A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007520545A (ja) * | 2004-02-05 | 2007-07-26 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | 抗アレルギー組成物及び関連方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1082340A1 (fr) | 2001-03-14 |
| WO2000058349A1 (fr) | 2000-10-05 |
| CA2329152A1 (fr) | 2000-10-05 |
| AU4053600A (en) | 2000-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3421970B2 (ja) | ペプチド免疫原 | |
| JP2002518038A (ja) | アレルギー治療用免疫原としてのペプチド組成物 | |
| JP2000152783A (ja) | 免疫活性ペプチドおよび抗体ならびに抗アレルギ―処置におけるそれらの使用 | |
| JP2002537403A (ja) | ＩｇＥのＣ−イプシロン−３またはＣ−イプシロン−４ドメイン由来のエピトープまたはミモトープ、その拮抗薬、及びそれらの治療的使用 | |
| JP2003514775A (ja) | 修飾された植物ウイルス及びその使用方法 | |
| AU2012277491B2 (en) | Contiguous overlapping peptides for treatment of ragweed pollen allergy | |
| EP0957111B1 (fr) | Protéines de liaison spécifiques pour le traitement des allergies canines | |
| JP2002540217A (ja) | イヌアレルギー用ペプチドワクチン | |
| US20040030106A1 (en) | Novel compounds and process | |
| US6734287B1 (en) | Specific binding proteins for treating canine allergy | |
| KR20020007313A (ko) | ＩｇＥ의 Ｃ-엡실론-2 도메인으로부터 유도된 에피토프또는 미모토프, 이들의 길항제 및 이들의 치료학적 용도 | |
| EP0955311A2 (fr) | Vaccin peptidique contre l'allergie des chiens | |
| JP2002539818A (ja) | イヌのアレルギーを治療するための特異的結合蛋白 | |
| US20040115220A1 (en) | Vaccine | |
| US20030170229A1 (en) | Vaccine | |
| US20030147906A1 (en) | Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of lgE, antagonists thereof, and their therapeutic uses | |
| CN107849119A (zh) | 用于治疗和预防IgE介导的疾病的疫苗 | |
| US20050214285A1 (en) | Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses | |
| MXPA00011938A (en) | Peptide composition as immunogen for the treatment of allergy |